Cargando…
The Double-Edge Role of the Addition of Adjuvant Chemotherapy to Concurrent Chemoradiotherapy in the Treatment of Nasopharyngeal Carcinoma
PURPOSE: To construct a prognostic index (PI) for overall survival (OS) to stratify nasopharyngeal carcinoma (NPC) into high-risk and low-risk groups. We also applied the model to investigate the role of the addition of adjuvant chemotherapy (AC) to concurrent chemoradiotherapy (CCRT) regimens for t...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007778/ https://www.ncbi.nlm.nih.gov/pubmed/32099476 http://dx.doi.org/10.2147/CMAR.S236128 |
_version_ | 1783495368718155776 |
---|---|
author | Liang, Zhong-Guo Zhang, Fan Yu, Bin-Bin Li, Ling Qu, Song Li, Ye Guan, Ying Liang, Ren-Ba Han, Lu Zhu, Xiao-Dong |
author_facet | Liang, Zhong-Guo Zhang, Fan Yu, Bin-Bin Li, Ling Qu, Song Li, Ye Guan, Ying Liang, Ren-Ba Han, Lu Zhu, Xiao-Dong |
author_sort | Liang, Zhong-Guo |
collection | PubMed |
description | PURPOSE: To construct a prognostic index (PI) for overall survival (OS) to stratify nasopharyngeal carcinoma (NPC) into high-risk and low-risk groups. We also applied the model to investigate the role of the addition of adjuvant chemotherapy (AC) to concurrent chemoradiotherapy (CCRT) regimens for the treatment of NPC. METHODS: A prognostic model was established based on a retrospective study of 362 patients from January 2008 to June 2011. The discriminative and calibration abilities of the model were evaluated by Harrell’s concordance index (C-index), and calibration curves. Bootstrapping was used to perform for internal validation. External validation was conducted using 324 patients diagnosed with NPC from July 2011 to December 2012 at the same institution. Survival analyses were performed between CCRT-AC and CCRT alone groups for the high-risk and low-risk groups. RESULTS: The primary PI comprised covariates that were associated with OS in the training cohort, including T stage, N stage, age, and plasma alkaline phosphatase (ALP). Internal and external validation showed that the discrimination of the PI for OS was significantly better than that of the 8th edition AJCC staging system. Discretization by using a fixed PI score cut-off of 407.96 determined from the training data set yielded high- and low-risk subgroups with distinct OS outcomes in the validation cohort. Adjuvant chemotherapy improved OS in high-risk patients (HR 0.620, 95% CI 0.408 to 0.941; P = 0.023) but increased the risk of distant metastasis (HR, 4.222, 95% CI, 0.959 to 18.585; P = 0.038) in low-risk patients. CONCLUSION: The proposed prognostic model achieved good prediction and calibration of OS for patients with NPC. The addition of adjuvant chemotherapy might be a double-edged sword, bringing survival benefit to high-risk patients but greater risk of distant metastasis to low-risk patients. |
format | Online Article Text |
id | pubmed-7007778 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-70077782020-02-25 The Double-Edge Role of the Addition of Adjuvant Chemotherapy to Concurrent Chemoradiotherapy in the Treatment of Nasopharyngeal Carcinoma Liang, Zhong-Guo Zhang, Fan Yu, Bin-Bin Li, Ling Qu, Song Li, Ye Guan, Ying Liang, Ren-Ba Han, Lu Zhu, Xiao-Dong Cancer Manag Res Original Research PURPOSE: To construct a prognostic index (PI) for overall survival (OS) to stratify nasopharyngeal carcinoma (NPC) into high-risk and low-risk groups. We also applied the model to investigate the role of the addition of adjuvant chemotherapy (AC) to concurrent chemoradiotherapy (CCRT) regimens for the treatment of NPC. METHODS: A prognostic model was established based on a retrospective study of 362 patients from January 2008 to June 2011. The discriminative and calibration abilities of the model were evaluated by Harrell’s concordance index (C-index), and calibration curves. Bootstrapping was used to perform for internal validation. External validation was conducted using 324 patients diagnosed with NPC from July 2011 to December 2012 at the same institution. Survival analyses were performed between CCRT-AC and CCRT alone groups for the high-risk and low-risk groups. RESULTS: The primary PI comprised covariates that were associated with OS in the training cohort, including T stage, N stage, age, and plasma alkaline phosphatase (ALP). Internal and external validation showed that the discrimination of the PI for OS was significantly better than that of the 8th edition AJCC staging system. Discretization by using a fixed PI score cut-off of 407.96 determined from the training data set yielded high- and low-risk subgroups with distinct OS outcomes in the validation cohort. Adjuvant chemotherapy improved OS in high-risk patients (HR 0.620, 95% CI 0.408 to 0.941; P = 0.023) but increased the risk of distant metastasis (HR, 4.222, 95% CI, 0.959 to 18.585; P = 0.038) in low-risk patients. CONCLUSION: The proposed prognostic model achieved good prediction and calibration of OS for patients with NPC. The addition of adjuvant chemotherapy might be a double-edged sword, bringing survival benefit to high-risk patients but greater risk of distant metastasis to low-risk patients. Dove 2020-02-04 /pmc/articles/PMC7007778/ /pubmed/32099476 http://dx.doi.org/10.2147/CMAR.S236128 Text en © 2020 Liang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Liang, Zhong-Guo Zhang, Fan Yu, Bin-Bin Li, Ling Qu, Song Li, Ye Guan, Ying Liang, Ren-Ba Han, Lu Zhu, Xiao-Dong The Double-Edge Role of the Addition of Adjuvant Chemotherapy to Concurrent Chemoradiotherapy in the Treatment of Nasopharyngeal Carcinoma |
title | The Double-Edge Role of the Addition of Adjuvant Chemotherapy to Concurrent Chemoradiotherapy in the Treatment of Nasopharyngeal Carcinoma |
title_full | The Double-Edge Role of the Addition of Adjuvant Chemotherapy to Concurrent Chemoradiotherapy in the Treatment of Nasopharyngeal Carcinoma |
title_fullStr | The Double-Edge Role of the Addition of Adjuvant Chemotherapy to Concurrent Chemoradiotherapy in the Treatment of Nasopharyngeal Carcinoma |
title_full_unstemmed | The Double-Edge Role of the Addition of Adjuvant Chemotherapy to Concurrent Chemoradiotherapy in the Treatment of Nasopharyngeal Carcinoma |
title_short | The Double-Edge Role of the Addition of Adjuvant Chemotherapy to Concurrent Chemoradiotherapy in the Treatment of Nasopharyngeal Carcinoma |
title_sort | double-edge role of the addition of adjuvant chemotherapy to concurrent chemoradiotherapy in the treatment of nasopharyngeal carcinoma |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007778/ https://www.ncbi.nlm.nih.gov/pubmed/32099476 http://dx.doi.org/10.2147/CMAR.S236128 |
work_keys_str_mv | AT liangzhongguo thedoubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma AT zhangfan thedoubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma AT yubinbin thedoubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma AT liling thedoubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma AT qusong thedoubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma AT liye thedoubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma AT guanying thedoubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma AT liangrenba thedoubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma AT hanlu thedoubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma AT zhuxiaodong thedoubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma AT liangzhongguo doubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma AT zhangfan doubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma AT yubinbin doubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma AT liling doubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma AT qusong doubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma AT liye doubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma AT guanying doubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma AT liangrenba doubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma AT hanlu doubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma AT zhuxiaodong doubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma |